Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
2013
Background
This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
142
Citations
NaN
KQI